,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-12-10 09:19:00,With the markets this choppy it's hard to think that some stocks can still be enjoying anything resembling a hot streak.,0.1081775650382042,0.1375516802072525,0.7542707920074463,neutral,-0.02937411516904831
1,2018-12-10 09:19:00,"But there are an elite group of strong buy stocks that are weathering the storm- and indeed, even posting gains.",0.7936546206474304,0.019409388303756714,0.18693597614765167,positive,0.7742452621459961
2,2018-12-10 09:19:00,"True, these stocks are now much harder to find.",0.03914814814925194,0.29189249873161316,0.6689593195915222,neutral,-0.2527443468570709
3,2018-12-10 09:19:00,"Even fundamentally strong stocks like Alphabet (NASDAQ: GOOG , NASDAQ: GOOGL ) have been hit hard by the recent market selloff.",0.024225989356637,0.9533841609954834,0.0223898533731699,negative,-0.9291581511497498
4,2018-12-10 09:19:00,"GOOGL, for example, is now posting a loss on a year-to-date basis.",0.038877326995134354,0.7840261459350586,0.17709653079509735,negative,-0.7451488375663757
5,2018-12-10 09:19:00,Also to note - these stocks have a strong setup going forward.,0.8937943577766418,0.014783472754061222,0.09142209589481354,positive,0.8790108561515808
6,2018-12-10 09:19:00,"Using TipRanks , I made sure to choose only stocks with a bullish ""strong buy"" analyst consensus.",0.09557679295539856,0.008813375607132912,0.8956098556518555,neutral,0.0867634192109108
7,2018-12-10 09:19:00,This is based on all ratings over the last three months.,0.016322970390319824,0.007176294922828674,0.9765007495880127,neutral,0.00914667546749115
8,2018-12-10 09:19:00,"What's more, we can use the average analyst price target to see how much upside potential remains ahead - and in the Street's analysis - to get a better grip on what's in store for these companies.",0.15119482576847076,0.007755189668387175,0.8410499691963196,neutral,0.1434396356344223
9,2018-12-10 09:19:00,"With that being said, let's dive into these strong-buy stocks now:

Salesforce.com (NYSE: CRM ) is the darling of Wall Street right now.",0.06095951423048973,0.017159216105937958,0.9218812584877014,neutral,0.04380029812455177
10,2018-12-10 09:19:00,And no doubt it's a popular pick for investors too.,0.3204554319381714,0.0121610127389431,0.66738361120224,neutral,0.308294415473938
11,2018-12-10 09:19:00,Shares are up 32% year-to-date.,0.9408654570579529,0.01900286041200161,0.04013167694211006,positive,0.9218626022338867
12,2018-12-10 09:19:00,An extremely upbeat earnings call at the end of November set the bulls roaring.,0.9083717465400696,0.03399420902132988,0.05763401836156845,positive,0.8743775486946106
13,2018-12-10 09:19:00,"Five-star Monness analyst Brian White ( Track Record & Ratings ) reiterated his ""buy"" rating post-earnings.",0.6189340949058533,0.01974763348698616,0.3613182306289673,positive,0.5991864800453186
14,2018-12-10 09:19:00,"""The tone of last night's call was the most bullish we've heard this earnings season from a tech company of size as Salesforce rides the wave of digital transformation initiatives around the world"" White told investors in his report.",0.854915976524353,0.06595084071159363,0.07913318276405334,positive,0.788965106010437
15,2018-12-10 09:19:00,"""During Dreamforce, [CEO] Marc Benioff described the economy as 'ripping' and he doubled down on his colorful commentary last night"" the analyst added.",0.06821783632040024,0.772797167301178,0.15898509323596954,negative,-0.7045793533325195
16,2018-12-10 09:19:00,The bullishness was justified following results that showed strength across the board.,0.9369199872016907,0.022354217246174812,0.04072578623890877,positive,0.9145657420158386
17,2018-12-10 09:19:00,"The Sales Cloud grew by 11% YoY, the Service Cloud 24%, the Marketing & Commerce Cloud by 37% and the Salesforce Platform & Other increased by 51%.",0.9534193873405457,0.016645142808556557,0.02993551641702652,positive,0.9367742538452148
18,2018-12-10 09:19:00,It's no surprise that Nomura's Chris Eberle highlights CRM as a top tech idea for 2019.,0.47191014885902405,0.01541041024029255,0.5126794576644897,neutral,0.45649972558021545
19,2018-12-10 09:19:00,"""Salesforce's continued market share gains across multiple end markets and breadth and depth of products, combined with its keen customer focus, recurring revenue model, and strategic value to its customers, make CRM a core long-term holding in the software space,"" he wrote.",0.9190781116485596,0.012099905870854855,0.0688219666481018,positive,0.906978189945221
20,2018-12-10 09:19:00,Interested in CRM stock?,0.0420115627348423,0.012155361473560333,0.9458330869674683,neutral,0.029856201261281967
21,2018-12-10 09:19:00,Get a free CRM Stock Research Report.,0.04343884810805321,0.006895845755934715,0.9496652483940125,neutral,0.03654300421476364
22,2018-12-10 09:19:00,Let's now turn to the risky - but potentially rewarding - world of biotechs.,0.21946042776107788,0.011732889339327812,0.7688066959381104,neutral,0.20772753655910492
23,2018-12-10 09:19:00,And what better stock to look at than Amarin (NASDAQ: AMRN ).,0.3505121171474457,0.015883781015872955,0.633604109287262,neutral,0.3346283435821533
24,2018-12-10 09:19:00,This is a company that has posted tremendous gains recently.,0.9096048474311829,0.014045869000256062,0.07634922862052917,positive,0.8955589532852173
25,2018-12-10 09:19:00,We are talking a whopping 320% year-to-date.,0.1557246744632721,0.010118905454874039,0.8341563940048218,neutral,0.14560577273368835
26,2018-12-10 09:19:00,"Luckily, the Street is confident that Amarin can keep delivering sizable gains.",0.938083827495575,0.0223896075040102,0.03952663019299507,positive,0.9156942367553711
27,2018-12-10 09:19:00,The average analyst price target of $35 suggests upside potential of over 100%.,0.6430191993713379,0.014514414593577385,0.3424663841724396,positive,0.6285048127174377
28,2018-12-10 09:19:00,"""Buckle Up, Because Vascepa Rxs Could Take Off Soon"" cheers Cantor Fitzgerald's Louise Chen ( Track Record & Ratings ).",0.11983924359083176,0.12539152801036835,0.7547692656517029,neutral,-0.005552284419536591
29,2018-12-10 09:19:00,"Vascepa is the first Pure EPA prescription Omega-3 clinically proven to lower very high triglycerides, without raising bad cholesterol.",0.6413298845291138,0.01274081226438284,0.3459292948246002,positive,0.6285890936851501
30,2018-12-10 09:19:00,Essentially it is an oral tablet of an extremely potent fish oil.,0.037871718406677246,0.008929436095058918,0.9531987905502319,neutral,0.028942283242940903
31,2018-12-10 09:19:00,"""We continue to think that the peak sales opportunity for Vascepa, post positive REDUCE-IT results, is still underappreciated"" writes Chen.",0.043799642473459244,0.9261766672134399,0.03002370335161686,negative,-0.882377028465271
32,2018-12-10 09:19:00,"Further share-driving catalysts include a potential EU partner for Vascepa, which could bring in a meaningful upfront payment to help offset cash burn- and continued salesforce expansion to 400 reps so Rx growth could increase even more in 2019 and beyond.",0.9521839022636414,0.01579318381845951,0.032022904604673386,positive,0.9363906979560852
33,2018-12-10 09:19:00,"â€¢ 10 Stocks to Sell That Are Melting Down Right Now

Chen has just reiterated her buy rating with a $35 price target (106% upside potential).",0.5599644780158997,0.029644738882780075,0.41039085388183594,positive,0.5303197503089905
34,2018-12-10 09:19:00,Get the AMRN Stock Research Report.,0.03078513592481613,0.0076823108829557896,0.9615325331687927,neutral,0.02310282550752163
35,2018-12-10 09:19:00,MongoDB (NASDAQ: MDB ) is one of the most popular databases for modern apps.,0.24202631413936615,0.01112116314470768,0.7468525171279907,neutral,0.23090514540672302
36,2018-12-10 09:19:00,"Also add to the picture MongoDB Atlas, the global cloud database on AWS, Azure and GCP.",0.051054637879133224,0.01049852930009365,0.9384468197822571,neutral,0.04055611044168472
37,2018-12-10 09:19:00,This is a stock with killer growth potential according to the Street.,0.6006839871406555,0.013174546882510185,0.38614144921302795,positive,0.5875094532966614
38,2018-12-10 09:19:00,"""We are raising our estimates and PT to $100 from $88 as our confidence grows in MongoDB's multiyear opportunity to sustain high growth in a large TAM"" cheers top KeyBanc analyst Brent Bracelin ( Track Record & Ratings ) on Dec. 4.",0.947008490562439,0.014836756512522697,0.03815479949116707,positive,0.9321717619895935
39,2018-12-10 09:19:00,"Bear in mind, this is one of the Top 20 analysts tracked by TipRanks, so he knows a thing or two about picking the best stocks.",0.14453089237213135,0.009904011152684689,0.845565140247345,neutral,0.13462688028812408
40,2018-12-10 09:19:00,"And according to Bracelin, this is a ""new class of database [that] should flourish on trillion-dollar IT transformation.""",0.5043192505836487,0.00999895203858614,0.48568177223205566,positive,0.4943203032016754
41,2018-12-10 09:19:00,Public cloud spending at the 60 largest vendors could triple to $314B by CY22.,0.9100587964057922,0.01901312544941902,0.07092814147472382,positive,0.8910456895828247
42,2018-12-10 09:19:00,These investments create a greenfield opportunity for a new class of database vendor.,0.9020563364028931,0.013656632974743843,0.08428704738616943,positive,0.8883997201919556
43,2018-12-10 09:19:00,"""We argue that MDB's leadership position in this new class of modern database should sustain high growth as the Company addresses one of the largest segments in software, the $45B-plus database TAM"" sums up the analyst.",0.9083636999130249,0.011610333807766438,0.08002592623233795,positive,0.8967533707618713
44,2018-12-10 09:19:00,Shares are up 180% year-to-date.,0.936697781085968,0.017923511564731598,0.04537871479988098,positive,0.9187742471694946
45,2018-12-10 09:19:00,Get the MDB Stock Research Report.,0.03326491266489029,0.007072244305163622,0.9596628546714783,neutral,0.026192668825387955
46,2018-12-10 09:19:00,Telecom stock Nexstar Media Group (NASDAQ: NXST ) isn't doing too badly either.,0.09492667764425278,0.5235170125961304,0.38155630230903625,negative,-0.428590327501297
47,2018-12-10 09:19:00,"Shares have put on a sprint over the last five days, prompted by a savvy acquisition agreement.",0.8829627633094788,0.04281037300825119,0.07422689348459244,positive,0.840152382850647
48,2018-12-10 09:19:00,"This is with a 19% gain over the last six months, and 8% year-to-date.",0.948701798915863,0.019093452021479607,0.032204825431108475,positive,0.9296083450317383
49,2018-12-10 09:19:00,Nexstar will snap up Chicago-based peer Tribune Media for about $4.1 billion in cash.,0.03377591073513031,0.28112363815307617,0.6851004362106323,neutral,-0.24734772741794586
50,2018-12-10 09:19:00,Following the deal Nexstar will take the crown as the largest regional US TV station operator.,0.5481159090995789,0.010451260954141617,0.44143277406692505,positive,0.5376646518707275
51,2018-12-10 09:19:00,Benchmark analyst Daniel Kurnos ( Track Record & Ratings ) gives the deal his seal of approval.,0.6836228370666504,0.014387312345206738,0.301989883184433,positive,0.6692355275154114
52,2018-12-10 09:19:00,"On the news, he raised his price target from $96 to $115 (17% upside potential).",0.8782171607017517,0.019205812364816666,0.10257703810930252,positive,0.8590113520622253
53,2018-12-10 09:19:00,"He is looking forward to Nexstar becoming the ""dominant player in the broadcast space.""",0.7413113713264465,0.01222176756709814,0.2464669644832611,positive,0.729089617729187
54,2018-12-10 09:19:00,"Longer-term, a buyout from private equity is now increasingly likely, Kurnos tells investors.",0.6045643091201782,0.011494295671582222,0.38394132256507874,positive,0.5930700302124023
55,2018-12-10 09:19:00,Meanwhile Barrington's James Goss reminds investors that Nexstar makes it onto the firm's research best ideas list.,0.8095032572746277,0.030551236122846603,0.15994545817375183,positive,0.7789520025253296
56,2018-12-10 09:19:00,"""Overall, valuation multiples for the company at its current rate of profitability and cash flow generation are particularly attractive"" he writes, adding ""Upside to our target remains sizable.""",0.8717165589332581,0.014534811489284039,0.11374855786561966,positive,0.8571817278862
57,2018-12-10 09:19:00,And all this with a $1.50 annual dividend to boot (at a 1.8% yield).,0.08295866847038269,0.009776131249964237,0.9072651267051697,neutral,0.07318253815174103
58,2018-12-10 09:19:00,"Overall, all seven analysts covering the stock are bullish right now.",0.20128633081912994,0.03258770331740379,0.7661259770393372,neutral,0.16869862377643585
59,2018-12-10 09:19:00,Get the NXST Stock Research Report.,0.02960636466741562,0.00845293328166008,0.9619407057762146,neutral,0.02115343138575554
60,2018-12-10 09:19:00,"Known as the ""llama biotech,"" Argenx SE (NASDAQ: ARGX ) is developing innovative therapies for severe autoimmune diseases and cancer.",0.3607944846153259,0.00810471922159195,0.6311007738113403,neutral,0.3526897728443146
61,2018-12-10 09:19:00,Yes you heard right - the Dutch-based company combines the diversity of the llama immune system with antibody engineering to develop drugs.,0.4816608726978302,0.00858916062861681,0.5097499489784241,neutral,0.47307172417640686
62,2018-12-10 09:19:00,"Most notably, Argenx's lead antibody, efgartigimod, reduces the number of bleeding events in patients with the autoimmune disorder primary immune thrombocytopenia.",0.7426115870475769,0.027857881039381027,0.22953052818775177,positive,0.7147536873817444
63,2018-12-10 09:19:00,"different antibogy, cusatuzumab, is being trialed for the treatment acute myeloid leukemia.",0.18166343867778778,0.017372844740748405,0.8009637594223022,neutral,0.16429059207439423
64,2018-12-10 09:19:00,"The antibody blocks the checkpoint protein CD70, stopping cancer cells from evading the immune system.",0.3007623851299286,0.34022021293640137,0.35901740193367004,neutral,-0.03945782780647278
65,2018-12-10 09:19:00,"""Acute myeloid leukemia continues to be an aggressive and deadly cancer of the blood and bone marrow with very high relapse rates,"" stated CEO Tim Van Hauwermeiren.",0.09289092570543289,0.22449378669261932,0.6826152801513672,neutral,-0.13160285353660583
66,2018-12-10 09:19:00,"""Cusatuzumab offers a novel mode of action targeting leukemic stem cellsâ€¦ and has shown a compelling response rate and tolerability profile to date.""",0.8824805617332458,0.012311606667935848,0.10520772635936737,positive,0.8701689839363098
67,2018-12-10 09:19:00,The big dogs are now paying attention.,0.09810192137956619,0.061971697956323624,0.8399264216423035,neutral,0.03613022342324257
68,2018-12-10 09:19:00,The company has just signed a global licensing deal for cusatuzumab with Johnson & Johnson (NYSE: JNJ ) and Janssen for $300M in cash and a $200M equity investment.,0.9179022908210754,0.013924384489655495,0.06817339360713959,positive,0.9039779305458069
69,2018-12-10 09:19:00,Argenx is also eligible for $1.3B in milestones and retained 50/50 U.S. profit share and double-digit OUS royalties.,0.9171293377876282,0.01458975113928318,0.06828098744153976,positive,0.9025396108627319
70,2018-12-10 09:19:00,"Shares surged 5% on the news, taking the stock's year-to-date gain to near 60%.",0.9469707608222961,0.023599328473210335,0.029429966583848,positive,0.923371434211731
71,2018-12-10 09:19:00,"Note that the stock scores 100% Street support right now, with eight recent buy ratings.",0.9022711515426636,0.022626157850027084,0.07510267198085785,positive,0.8796449899673462
72,2018-12-10 09:19:00,The average analyst price target of $140 indicates 33% upside potential lies ahead.,0.6940058469772339,0.027487926185131073,0.27850624918937683,positive,0.6665179133415222
73,2018-12-10 09:19:00,Get the ARGX Stock Research Report.,0.034190692007541656,0.007748371921479702,0.9580609202384949,neutral,0.02644231915473938
74,2018-12-10 09:19:00,Fast food giant McDonald's Corporation (NYSE: MCD ) is staging a comeback.,0.8329086899757385,0.026342758908867836,0.14074857532978058,positive,0.8065659403800964
75,2018-12-10 09:19:00,"We are looking at a stream of recent buy ratings, and an upgrade to boot.",0.3173985779285431,0.009135107509791851,0.6734663248062134,neutral,0.30826348066329956
76,2018-12-10 09:19:00,Morgan Stanley's John Glass ( Track Record & Ratings ) is the analyst behind the upgrade.,0.41360506415367126,0.009429420344531536,0.5769655108451843,neutral,0.40417563915252686
77,2018-12-10 09:19:00,"He advises ""buying the McDonald's of the future today.""",0.07397583872079849,0.01628616824746132,0.9097379446029663,neutral,0.05768967047333717
78,2018-12-10 09:19:00,"The reason is simple - successful modernization of stores: ""We are endorsing the notion that McDonald's massive store modernization efforts, first rolled out in select international markets and now in the U.S. (its single largest market), will begin to pay off in '19 and should produce best in class sales results for more years to come,"" Glass told investors.",0.9440291523933411,0.0147683871909976,0.04120253026485443,positive,0.929260790348053
79,2018-12-10 09:19:00,"And that's not all, given the choppy market conditions, Glass sees MCD as a savvy defensive stock pick.",0.6226578950881958,0.014175080694258213,0.36316704750061035,positive,0.608482837677002
80,2018-12-10 09:19:00,"""McDonald's provides a stabilizing, defensive counterbalance in a volatile market environment,"" Glass said.",0.9021304845809937,0.01517371367663145,0.08269582688808441,positive,0.8869567513465881
81,2018-12-10 09:19:00,"â€¢ 10 Defensive Stocks to Protect Your Portfolio in 2019

Citing the company's ""structurally improving"" business model, the Morgan Stanley analyst also ramped up his price target from $173 to $210.",0.8804692029953003,0.017298337072134018,0.1022324189543724,positive,0.863170862197876
82,2018-12-10 09:19:00,This translates into 15% upside potential from current levels.,0.8622997403144836,0.01884625107049942,0.11885398626327515,positive,0.8434534668922424
83,2018-12-10 09:19:00,"Year-to-date shares have improved 6%, with am 11% gain in just the last three months alone.",0.9581779837608337,0.021891441196203232,0.019930550828576088,positive,0.9362865686416626
84,2018-12-10 09:19:00,Get the MCD Stock Research Report.,0.03313571959733963,0.007036208640784025,0.9598280191421509,neutral,0.026099510490894318
85,2018-12-10 09:19:00,"Last but not least we have BioCryst Pharmaceuticals (NASDAQ: BCRX ), a biotech that has made a whopping 80%-plus gain year-to-date.",0.8789769411087036,0.013168543577194214,0.10785456746816635,positive,0.865808367729187
86,2018-12-10 09:19:00,"The company's lead drug, BCX7353, is in phase II trials for severe swelling disorder (HAE), while the company's first approved drug, Rapivab, is a powerful treatment for influenza.",0.5243790745735168,0.01277706678956747,0.4628438651561737,positive,0.511601984500885
87,2018-12-10 09:19:00,"""Even with the ~30% share appreciation in the last two weeks, we believe BCRX shares continue to undervalue the likelihood of success and future market opportunity for lead drug BCX7353"" writes RBC Capital's Brian Abrahams ( Track Record & Ratings ).",0.9480383992195129,0.025105074048042297,0.026856519281864166,positive,0.9229333400726318
88,2018-12-10 09:19:00,Especially so given the drug's differentiation from competitors as an orally delivered HAE treatment - which currently represents a high unmet need.,0.6385421752929688,0.013834587298333645,0.34762316942214966,positive,0.6247075796127319
89,2018-12-10 09:19:00,"This stock can excel from both HAE prophylaxis, and in on-demand treatment, a potential market the analyst increasingly believes is being overlooked.",0.22679613530635834,0.013604201376438141,0.7595996260643005,neutral,0.2131919264793396
90,2018-12-10 09:19:00,"""We are updating our BCRX model to reflect what we believe could be an additional near-$200M in potential annual out- year revenues from the on-demand setting"" he concludes.",0.802718997001648,0.011145664379000664,0.18613526225090027,positive,0.7915733456611633
91,2018-12-10 09:19:00,"As a result, Abrahams raises his price target to $16 (from $10), and notes that BCRX remains a favorite small-cap idea into 2019.",0.9042375087738037,0.017240863293409348,0.07852164655923843,positive,0.8869966268539429
92,2018-12-10 09:19:00,Get the BCRX Stock Research Report.,0.029098769649863243,0.007852651178836823,0.9630486369132996,neutral,0.02124611847102642
93,2018-12-10 09:19:00,"TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more.",0.030375348404049873,0.006200163159519434,0.9634244441986084,neutral,0.024175185710191727
94,2018-12-10 09:19:00,See what the experts are saying about your stocks now at TipRanks.com .,0.026852857321500778,0.012680605985224247,0.9604665040969849,neutral,0.014172251336276531
95,2018-12-10 09:19:00,"As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities.",0.009872709400951862,0.022091234102845192,0.9680359959602356,neutral,-0.01221852470189333
96,2018-12-10 09:19:00,"â€¢ 10 Stocks to Sell That Are Melting Down Right Now
â€¢ 10 Chinese Stocks That Are Worth a Gamble In 2019

The post 7 Hot Stocks to Buy in a Cold Market appeared first on InvestorPlace .",0.22378496825695038,0.06257052719593048,0.7136445045471191,neutral,0.1612144410610199
97,2018-12-10 09:19:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
